|
شركة Lyra Therapeutics، Inc. (LYRA) تقييم DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Lyra Therapeutics, Inc. (LYRA) Bundle
تم تصميم حاسبة DCF الخاصة بنا (LYRA) الخاصة بنا ، بتقييم تقييم Lyra Therapeutics ، Inc. باستخدام البيانات المالية الحديثة ومرونة كاملة لتعديل جميع المعلمات الرئيسية للتوقعات المحسنة.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .3 | 1.4 | 1.6 | 2.0 | 2.6 | 3.3 | 4.3 | 5.5 |
| Revenue Growth, % | 0 | 0 | 0 | 378.25 | 14.31 | 28.58 | 28.58 | 28.58 | 28.58 | 28.58 |
| EBITDA | -16.5 | -22.1 | -42.6 | -53.9 | -65.3 | -.4 | -.5 | -.7 | -.9 | -1.1 |
| EBITDA, % | 100 | 100 | -14952.28 | -3956.2 | -4188.06 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | .0 | .1 | 1.0 | 1.1 | .3 | 1.6 | 2.0 | 2.6 | 3.4 | 4.3 |
| Depreciation, % | 100 | 100 | 351.23 | 78.28 | 17.84 | 79.23 | 79.23 | 79.23 | 79.23 | 79.23 |
| EBIT | -16.5 | -22.2 | -43.6 | -55.0 | -65.5 | -.4 | -.5 | -.7 | -.9 | -1.1 |
| EBIT, % | 100 | 100 | -15303.51 | -4034.48 | -4205.91 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 9.8 | 74.6 | 45.7 | 97.9 | 102.8 | 2.0 | 2.6 | 3.3 | 4.3 | 5.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .8 | 1.0 | 1.3 | 1.7 | 2.2 |
| Account Receivables, % | 100 | 100 | 0 | 0 | 0 | 40 | 40 | 40 | 40 | 40 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .8 | 1.0 | 1.3 | 1.7 | 2.2 |
| Inventories, % | 100 | 100 | 0 | 0 | 0 | 40 | 40 | 40 | 40 | 40 |
| Accounts Payable | 1.1 | .9 | 3.1 | 2.6 | 3.1 | 2.0 | 2.6 | 3.3 | 4.3 | 5.5 |
| Accounts Payable, % | 100 | 100 | 1096.49 | 191.93 | 200.96 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.2 | -1.8 | -3.4 | -.2 | -1.0 | -.7 | -.9 | -1.2 | -1.5 | -2.0 |
| Capital Expenditure, % | 100 | 100 | -1187.72 | -12.03 | -67.2 | -35.85 | -35.85 | -35.85 | -35.85 | -35.85 |
| Tax Rate, % | -0.09421759 | -0.09421759 | -0.09421759 | -0.09421759 | -0.09421759 | -0.09421759 | -0.09421759 | -0.09421759 | -0.09421759 | -0.09421759 |
| EBITAT | -16.3 | -22.1 | -42.5 | -55.0 | -65.6 | -.4 | -.5 | -.7 | -.8 | -1.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -15.4 | -24.0 | -42.7 | -54.6 | -65.8 | -2.3 | .7 | .9 | 1.2 | 1.5 |
| WACC, % | 4.26 | 4.29 | 4.22 | 4.3 | 4.3 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 2 | |||||||||
| Terminal Value | 69 | |||||||||
| Present Terminal Value | 56 | |||||||||
| Enterprise Value | 57 | |||||||||
| Net Debt | 5 | |||||||||
| Equity Value | 53 | |||||||||
| Diluted Shares Outstanding, MM | 50 | |||||||||
| Equity Value Per Share | 1.06 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real LYRA financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe the effect of your inputs on Lyra Therapeutics’ valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive Financial Data: Gain access to precise pre-loaded historical figures and future forecasts for Lyra Therapeutics, Inc. (LYRA).
- Adjustable Forecast Parameters: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Automatic recalculations for DCF, Net Present Value (NPV), and cash flow assessments.
- Interactive Dashboard: User-friendly charts and summaries for a clear view of your valuation outcomes.
- Suitable for All Skill Levels: Designed with an intuitive layout for investors, CFOs, and consultants alike.
How It Works
- 1. Download the Model: Obtain and open the Excel template containing Lyra Therapeutics, Inc.'s (LYRA) financial data.
- 2. Adjust Key Variables: Modify essential inputs such as revenue growth, discount rate, and capital investments.
- 3. Analyze Results in Real-Time: The DCF model automatically computes the intrinsic value and net present value.
- 4. Explore Different Scenarios: Evaluate various projections to understand potential valuation impacts.
- 5. Present with Assurance: Deliver expert valuation analysis to inform your strategic choices.
Why Choose This Calculator?
- Comprehensive Tool: Features DCF, WACC, and financial ratio analyses tailored for Lyra Therapeutics, Inc. (LYRA).
- Customizable Inputs: Modify yellow-highlighted cells to explore different financial scenarios.
- Detailed Insights: Automatically computes Lyra Therapeutics' intrinsic value and Net Present Value.
- Preloaded Data: Utilizes historical and projected data for precise calculations.
- Professional Quality: Perfect for financial analysts, investors, and consultants focusing on Lyra Therapeutics, Inc. (LYRA).
Who Should Use This Product?
- Pharmaceutical Students: Understand drug development processes and apply theoretical knowledge using real-world examples.
- Researchers: Integrate advanced therapeutic models into studies or academic projects.
- Healthcare Investors: Evaluate your investment strategies and analyze market potential for Lyra Therapeutics, Inc. (LYRA).
- Market Analysts: Enhance your analysis with a customizable model tailored for biotech evaluations.
- Healthcare Entrepreneurs: Discover how innovative companies like Lyra Therapeutics, Inc. (LYRA) are positioned within the industry.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Lyra Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Lyra Therapeutics, Inc. (LYRA).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.